Prasad Chodavarapu

Co-Founder @AganithaAI | Transforming BioPharma R&D with Computational Biology/Chemistry and AI | Building multi-disciplinary teams | Author

[Prasad Chodavarapu @Omics_Chap]

Looking forward to speaking today at the Claude Community event in Hyderabad on:

🎤 Beyond Automation: Architecting the Agentic Enterprise

I'll be sharing implementation lessons from human–agent workflows for scientific R&D at @AganithaAI

https://t.co/jM1czsIRlg

[Prasad Chodavarapu @Omics_Chap]

Looking forward to the session at AIPM in @iitmadras today. I'm planning to show in action, Aganitha Igniva™ agents for: hypothesis validation, target elucidation, protocol generation, MD results analysis, listening to voices of patients, HCPs and KOLs, and much more.

[Aganitha.ai @AganithaAI]

🚀Real-World Applications of #AgenticAI Accelerating #Biopharma R&D and Care

👉 Join us at AIPM-India 2025 in @iitmadras to see in action, Igniva™ AI agents, built on 5+ years of global biopharma R&D collaborations by 100+ researchers at Aganitha

[Prasad Chodavarapu @Omics_Chap]

I’ve seen firsthand how many painful iterations multi-disciplinary teams go through to decode the biology hidden in #SingleCell #Omics data.

There has to be a faster way — one built for better collaboration, powered by #AI and #LLMs.

#DISTILL is our shot at doing this right.

[Aganitha.ai @AganithaAI]

🔬 DISTILLing Complex Biology in the #SingleCell & #AgenticAI Era

Why should single cell #omics analysis still take months, even in 2025?

In this video, Ananya Jana explains the core challenges single cell researchers face today and how DISTLL™ accelerates journey to insights.

[Prasad Chodavarapu @Omics_Chap]

If we’re to distribute the fruits of modern #science to all of humanity, we must find ways to scale access to expertise. #AI can be a powerful enabler on this path — augmenting human insight, accelerating development, and broadening accessibility.

[Aganitha.ai @AganithaAI]

📢 Personalized #GeneTherapy is here. #AI can help widen access.

A few days after KJ Muldoon was born, he was diagnosed with a rare genetic disorder. Doctors told his family:

“Your son is very sick. The best place in the world to be when your child is sick is next door.”

[Prasad Chodavarapu @Omics_Chap]

First in a series of #Igniva #AgenticAI demos we'll be posting. This one recaps the analysis in a blog by @doctorveera on a genetic variant in NOTCH3 that's associated with Stroke in South Asian populations.

[Aganitha.ai @AganithaAI]

🧬 Excited to share a glimpse into the future of #Biopharma R&D with Aganitha #Igniva #AgenticAI Demo

Igniva is our suite of research agents that integrate #LLMs with scientific data, tools & workflows to tackle complex problems like variant effect analysis.

[Prasad Chodavarapu @Omics_Chap]

That’s probably it! Era of manual programming of software may now be in the past.

[Prasad Chodavarapu @Omics_Chap]

Glad to see multi-cell, multi-modal model attempted.

C2S-scale extends Cell2Sentences (C2S), a previous #virtualcell model, to 27B parameters, training on a 1B token Multi-modal dataset with a context length of 8192 (this needs to increase too).

https://t.co/pjy8MK1cRP

[Prasad Chodavarapu @Omics_Chap]

Reflecting on #virtualcell: Given that no cell is an island, what's the chance of inferring biology looking at just a single cell's transcriptome?

Quoting https://t.co/ulaeS2GcbG: "After all, we do not have healthy or diseased annotations for individual cells."

#singlecell #AI

[Prasad Chodavarapu @Omics_Chap]

@BiologyAIDaily Preprint says, "After all, we do not have healthy or diseased annotations for individual cells; instead, we rely on whether the cells were derived from healthy or diseased donors."

Given that no cell is an island, can #virtualcell models infer biology looking at just one cell?

[Prasad Chodavarapu @Omics_Chap]

Talk to us at #PMWC25 to see demos and know more first hand.
https://t.co/eD2eISYhMR

[Aganitha.ai @AganithaAI]

Aganitha Launches Igniva™: A Suite of AI Agents for Therapeutic Design and Research

Igniva™ #AgenticAI analyzes & reasons over biological, chemical & clinical datasets, knowledge bases, and computational & AI models, with human experts in the loop.

https://t.co/qfZGpRCOyY

[Prasad Chodavarapu @Omics_Chap]

In the panel discussion at #BiologicsWorkshop2025 in Goa last week, discussing #AI for #Bioprocess. Consensus was that AI adoption for meeting operational needs is proving easier than adoption for process optimisation given the regulated nature of bioprocesses.

[Prasad Chodavarapu @Omics_Chap]

Loved the interactions at #BiologicsWorkshop2025 in Goa last week. I shared three case studies illustrating convergence of #AI and #DeepScience in the modeling and optimization of synthesis processes for mAb, mRNA and Gene therapies.

[Aganitha.ai @AganithaAI]

📢 Join us at #PMWC25 to talk about AI in BioPharma R&D

Vikram Duvvoori (@VikramDu), CEO of https://t.co/kuQkDWaLYH, will be presenting case studies showing how #GenAl & in silico modeling are mining insights from deep science to accelerate #BioPharma R&D. See you there.

[Prasad Chodavarapu @Omics_Chap]

@BiologyAIDaily Tweetorial at https://t.co/z6jM42OZ1f

[Aganitha.ai @AganithaAI]

At Aganitha, we are applying deep tech to learn from & build on the datasets generated by deep science.

Happy to share a preprint describing how we used #GenAI to improve design of blood-brain-barrier (#BBB) penetrating #AAV viral vectors for gene therapies in brain disorders.

[Prasad Chodavarapu @Omics_Chap]

In the age of CRISPR, Gen AI & population-scale health data, BioPharma R&D is drinking from a firehose and understandably, getting drenched in the process without quenching the thirst for approved therapies. DBTIPS™ is our attempt to make this challenge more tractable.

[Aganitha.ai @AganithaAI]

🧬 Announcing Aganitha Disease Biomarker & Target Insights Platform & Services (#DBTIPS™)

Details at
https://t.co/jH3oIFLono

Summary in 🧵👇

#DrugDiscovery #Biomarkers #PrecisionMedicine #AI #Biopharma

[Prasad Chodavarapu @Omics_Chap]

Representing @AganithaAI at @Capgemini LSH @nasscomai @IFCCI1 hosted #AIEHyderabad event on "Accelerating drug discovery and development", answering questions on application of #GenerativeAI and progress in #PrecisionMedicine

[Aganitha.ai @AganithaAI]

Delighted to share results from our Molecular Dynamics (MD) simulations investigating why Siponimod, a FDA-approved drug for relapsing forms of Multiple Sclerosis, activates its GPCR target, S1PR1 but not S1PR2, an off-target from the same family.

🧵👇

https://t.co/pYBGS04Tlj

[Prasad Chodavarapu @Omics_Chap]

🚀 @AganithaAI ARC™ Framework combines LLM capabilities with #biopharma expertise, offering customized tools and services. See attached 🧵for details and demos.

[Aganitha.ai @AganithaAI]

🔬 Unlock the Power of #LLM in #Biopharma with Aganitha’s ARC™ Framework

1. Auto-analyze #Omics datasets
2. Discover novel drug targets & biomarkers
3. Generate & review regulatory submissions & contracts
4. Reduce hallucinations

See https://t.co/ctxUyDEJVZ

Demos in 🧵

[Aganitha.ai @AganithaAI]

Excited to announce Aganitha’s collaboration with @ccmb_csir to apply Generative AI solutions for designing novel therapeutics and research antibodies addressing needs in multiple disease areas.

More details at https://t.co/UCaIIVWIiY

[Prasad Chodavarapu @Omics_Chap]

Absolutely! AI is everywhere in science now. AI is helping us mine insights from large datasets produced by high-throughput experiments. We are in a Deep Science + Deep Tech era. We explain with a few examples in a recent blog at

https://t.co/1dHOJXb9xY

[The Royal Society @royalsociety]

The 'Science in the Age of AI' report explores the opportunities and challenges of machine learning and large-language models as transformative tools for 21st century research. Read the full report now: https://t.co/7LBvUnyfrI